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Abstract
Aims: Stimulated release of tissue-type plasminogen activator (t-PA) is pivotal for an intravascular fibrinolytic response and
protects the circulation from occluding thrombosis. Hence, an impaired t-PA production is associated with increased risk for
atherothrombotic events. A pharmacological means to stimulate the production of this enzyme may thus be desirable. We
investigated if the anti-epileptic drug valproic acid (VPA) is capable of enhancing t-PA expression in vitro in vascular
endothelial cells, and further examined if its histone deacetylase (HDAC)-inhibitory activity is of importance for regulating t-
PA expression.
Methods and Results: Human endothelial cells were exposed to valproic acid and t-PA mRNA and protein levels were
quantified. Potential changes in histone acetylation status globally and at the t-PA promoter were examined by western blot
and chromatin immunoprecipitation. Valproic acid dose-dependently stimulated t-PA mRNA and protein expression in
endothelial cells reaching a 2–4-fold increase at clinically relevant concentrations and 10-fold increase at maximal
concentrations. Transcription profiling analysis revealed that t-PA is selectively targeted by this agent. Augmented histone
acetylation was detected at the t-PA transcription start site, and an attenuated VPA-response was observed with siRNA
knock of HDAC3, HDAC5 and HDAC7.
Conclusions: Valproic acid induces t-PA expression in cultured endothelial cells, and this is associated with increased
histone acetylation at the t-PA promoter. Given the apparent potency of valproic acid in stimulating t-PA expression in vitro
this substance may be a candidate for pharmacological modulation of endogenous fibrinolysis in man.
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Introduction
Myocardial infarctions and a substantial part of ischemic strokes
arecausedbyintravascularclotformation.Whenaclottingprocessis
initiated in an otherwise healthy blood vessel, the surrounding
endothelium is activated and releases large amounts of the
fibrinolytic enzyme tissue-type plasminogen activator (t-PA) causing
the clot to dissolve. Recent data from the Framingham Heart Study
support the hypothesis that an impaired t-PA release may increase
the risk for permanent flow-arresting thrombi, as the t-PA enhancer
27,351C/T polymorphism (generating a low-secretor phenotype)
was found to be associated with a more than 3-fold adjusted
increased riskfor myocardial infarction [1]. A similar association was
previously reported by us [2]. This indicates that in case of an
impaired endogenous fibrinolysis due to a reduced capacity for t-PA
release, intravascular thrombus formation may propagate and lead
toarterial occlusion and tissueinfarction. Inline with thishypothesis,
t-PA release has been found to be defective in certain conditions
associated with increased risk of thrombotic events, such as
hypertension [3,4,5], obesity [6] and coronary atherosclerosis [7,8].
Our group has previously demonstrated that it is possible to
restore a suboptimal t-PA response by treating the underlying
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pharmacological tool to stimulate endogenous local fibrinolysis
also in cases when the patho-physiological mechanism causing the
attenuated t-PA release is unknown or inaccessible for interven-
tion. The fact that t-PA expression has been reported to be
powerfully up-regulated by the classical histone deacetylase
inhibitors (HDACi) butyrate and Trichostatin A (TSA) [9,10], as
well as to the newer HDACi MS-275 [11], suggests that the t-PA
gene could be sensitiveto changesinhistone acetylation status.Post-
translational acetylation status of histone proteins is determined by
the concerted action of two families of enzymes, the histone acetyl
transferases (HATs) whichcatalyzethe transfer of an acetyl group to
lysine residues of the histone tails, and histone deacetylases
(HDACs) which catalyze the removal of subsequent acetyl groups.
The combined action of these two groups of enzymes results in a
dynamic regulation of the acetylation status of histones, which
influence the transcriptional competence of chromatin (reviewed in
[12]). Inhibition of HDACs is considered to prevent histone
deacetylation hence shifting histone acetylation status in favor of a
more acetylated and permissive chromatin state.
Valproic acid (valproate, 2-propylpentanoic acid, VPA) is a
clinically available anti-epileptic and mood-stabilizing drug which
is also suggested to be an HDAC inhibitor in several transformed
cell lines [13,14] as well as primary cells including endothelial cells
[15]. In this study, we investigated the hypothesis that VPA
functions as an HDAC inhibitor in endothelial cells and that
HDAC inhibition by VPA could increase t-PA production in vitro.
If so, VPA may be a promising candidate for modulation of local
endogenous fibrinolytic capacity in vivo.
Materials and Methods
Chemicals
Na-valproate was purchased from Sigma-Aldrich (St Louis,
MO, USA) and stock solutions (0.3 M) were prepared in complete
endothelial cell culture medium (EGM-2, Lonza, Basel, Switzer-
land) and stored at 270uC. Valpromide (2,2-Di-n-propylaceta-
mide) was ordered from Alfa Aesar (Karlsruhe, Germany) and
stock solutions (1.5 M) were prepared in DMSO and stored at
220uC. The compounds were diluted in complete endothelial cell
culture medium immediately before use.
Cell culture and experimental design
The investigation conformed to the principles outlined in the
Declaration of Helsinki for the use of human tissues, and the use of
cells from human umbilical cords was approved by the Regional
Ethics Review Board of Gothenburg (approval reference number
449–93). Verbal informed consent was obtained from the donors
regarding the use of umbilical cord cells for research purposes.
Given that the study material was non-identifiable, written consent
was uncalled for and this consent procedure was approved by the
ethical review board. Human umbilical vein endothelial cells
(HUVECs) were prepared by collagenase treatment [16] of fresh
umbilical cords obtained from the maternity ward of the
Sahlgrenska University hospital. Cells were cultured in EGM-2
medium and all experiments were performed in passages 1 or 2.
Human coronary artery endothelial cells (HCAEC) were pur-
chased from Lonza and cultured in EGM-2 complete medium
supplemented with fetal bovine serum to a total serum content of
5%. HCAEC were used in passage 5. Confluent HUVECs or
HCAECs were exposed to optimal concentrations of VPA in
complete medium. After incubation with the substance for up
to 72 h (with fresh medium and inhibitors added every 24 h),
cells and conditioned media were harvested. Cell cultures were
performed in duplicate and all experiments (except HDAC9
siRNA experiments, n=2) were performed on cells from a
minimum of 3 individuals.
Real-Time RT-PCR
Total RNA was prepared using RNeasy Mini RNA kit (Qiagen,
Hilden, Germany) and genomic DNA was removed using RNase-
free DNase I set (Qiagen). Levels of t-PA mRNA were analyzed
with real-time RT-PCR, performed on an Applied Biosystems
7500 Fast Real-Time PCR System using cDNA and Taqman
reagents obtained from Applied Biosystems (Foster City, CA,
USA). Hypoxanthine phosphoribosyl transferase (HPRT) was used
as endogenous internal standard, except in HDAC7 siRNA
experiments where Beta-glucuronidase (GUSB) was employed.
The primer sequences were as follows: t-PA Fp: 59-GGC CTT
GTC TCC TTT CTA TTC G-39, t-PA Rp: 59-AGC GGC TGG
ATG GGT ACA G-39, and t-PA probe 59-TGA CAT GAG CCT
CCT TCA GCC GCT-39 The t-PA probe was dual-labeled with
59-reporter dye FAM (6-carboxy-fluorescein) and 39-quencher
dye TAMRA (6-carboxy-tetramethyl-rhodamine). HPRT and
GUSB transcripts were detected using Gene Expression Assays
Hs99999909_m1 and Hs99999908_m1 (Applied Biosystems),
respectively. Knock-down of class I, IIa and IV HDAC mRNAs
were confirmed with the following Gene Expression Assays:
Hs02621185_s1 (HDAC1), Hs00231032_m1 (HDAC2), Hs00187320
_m1 (HDAC3), Hs00954353_g1 (HDAC8), Hs01041648_m1
(HDAC4), Hs00608366_m1 (HDAC5), Hs00248789_m1 (HDAC7),
Hs00206843_m1 (HDAC9) and Hs00227335_m1 (HDAC11). u-PA
and von Willebrand factor mRNA levels were detected using Gene
Expression Assay Hs00170182_m1 and Hs00169795_m1 respectively,
and PAI-1 mRNA was detected using the primers PAI-1 Fp 59-GGC
TGA CTT CAC GAG TCT TTC A-39,R p5 9-TTC ACT TTC
TGC AGC GCC T-39 and FAM/TAMRA labeled probe 59-ACC
AAG AGC CTC TCC ACG TCG CG-39.
Enzyme-linked immunosorbent assay
Endothelial cells in culture are known to constitutively secrete
the majority of synthesized t-PA [17], making conditioned media a
suitable source for quantification of t-PA protein. Conditioned
medium from cell cultures was collected, centrifuged (10 0006g,
10 min, 4uC) to remove cell debris, transferred to fresh tubes and
stored at 270uC. Concentrations of t-PA antigen in conditioned
media were determined using the commercially available Trini-
Lize t-PA antigen ELISA (Trinity Biotech, Bray, Ireland)
according to manufacturer’s protocol.
Western blot analysis
Cells were harvested in Laemmli sample buffer with 5% b-
merkaptoethanol, sonicated and boiled before being resolved on a
pre-cast 10–20% Tris-Glycine gel (Lonza) and transferred by
electro blotting onto polyvinylidene fluoride membranes. Mem-
branes were incubated with primary antibodies to pan acetylated
H3 (#39139) and acetylated H4 (#39243) (both from Active
Motif, Carlsbad, CA, USA) as well as to total histone H3
(#ab1791, AbCam, Cambridge, UK) and H4 (#05-858, Milli-
pore, Billerica, MA, USA). Proteins were detected according to
manufacturer’s protocols and visualized using chemiluminescence
(SuperSignal, Pierce Biotechnology, Rockford, IL, USA).
Chromatin Immunoprecipitation Assay
HUVECs were grown on 15 cm plates until confluent and then
stimulated with VPA for 24 h. After washing, cross-linking (1%
formaldehyde in PBS, 5 min), glycine quenching, and further
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10 mM EDTA, 50 mM Tris-HCl pH 8,0) supplemented with
protease inhibitors and immediately sonicated to shear chromatin
to a length of approximately 100–500 bp (as determined by
capillary electrophoresis on an Agilent 2100 bioanalyzer) using a
Diagenode Biorupture (30 min of 30 s on/off at 4uC). Insoluble
material was removed by centrifugation (12 0006g, 10 min) and
chromatin concentration was determined using the Quant-iT
dsDNA BR kit and Qubit fluorometer (Invitrogen Life Technol-
ogies, Carlsbad, CA, USA). Immunoprecipitation was performed
on 1 mg of sheared chromatin, corresponding to approximately
5610
5 cells per IP. Chromatin was diluted to 500 ml in dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl pH 8,0, 167 mM NaCl) and pre-cleared by
the addition of 20 ml Protein A-coupled magnetic beads (Invitro-
gen) for 2 h on constant rotation. Four mg of each antibody and
20 ml of protein A beads were pre-incubated for 2 h before the
addition of the pre-cleared chromatin and the reactions were left
over night at 4uC on a rotating platform. The antibodies used were
the same as for western blot detecting pan acetylated histone H3
(K9, 14, 18, 23, and 27) or pan acetylated histone H4 (K5, 8, 12,
16). For detection of mono-lysine acetylation the following
antibodies from Active Motif were used: acH3K9: #39137,
acH3K14: #39697, acH3K18: #39587, acH3K23: #39131,
acH3K27: #39133, acH4K5: #39169, acH4K12: #39165, and
acH4K16: #39167. The antibody for acH4K8 (07-328) was
purchased from Millipore. A no-antibody control reaction was
included in each run. After extensive washing, captured DNA was
eluted from the beads by proteinase K digestion (Sigma-Aldrich)
and purified using spin column purification (Nucleospin Extract II,
Macherey-Nagel, Du ¨ren, Germany). Isolated DNA fragments
were quantified using real-time PCR with SYBR Green detection
and the following primers spanning (246 to +92) the t-PA major
transcription initiation site (TIS) [18] (+66 to +203 according to
the minor TIS): Forward primer 59-ACCCCCTGCCTGG-
AAACTTA-39 and reverse primer 59-GGTACAGAAACCC-
GACCTACCA-39. Levels of precipitated DNA are displayed as
percentage of input (non-precipitated control) corrected for
background-(No antibody) precipitated DNA.
Short interfering RNA transfection
Short interfering RNA (siRNA) specific for class I HDACs
(HDAC1, HDAC2, HDAC3 and HDAC8), class IIa HDACs
(HDAC4, HDAC5, HDAC7 and HDAC9) and class IV HDAC
(HDAC11) were obtained from Dharmacon (Thermo Fisher
Scientific, Lafayette, CO, US). The following ON-TARGETplus
SMART pool siRNA sets were used: HDAC1; L-003493,
HDAC2; L-003495, HDAC3; L-003496, HDAC8; L-003500,
HDAC4; L-003497, HDAC5; L-003498, HDAC7; L-009330,
HDAC9; L-005241 and HDAC11; L-004258. HUVECs were
plated in 24-well plates in EGM-2 medium without antibiotics and
incubated overnight. The following day, at about 70% confluency,
cells were transfected. For each stimulation, siRNA (final
concentration 10 nM, except in HDAC9 experiments final
concentration=40 nM) and 1 ml DharmaFECT 4 transfection
reagent (Dharmacon) were separately incubated in 50 ml Opti-
MEM (Invitrogen) for 5 min, thereafter combined and incubated
for 20 min and finally diluted in 400 ml EGM-2 without antibiotics
before being added to cells. A second transfection was made 24 h
later. Forty-eight hours after the second siRNA treatment, the cells
were treated with 3 mM VPA or control medium and 24 h later
mRNA was extracted and analyzed by real-time PCR to
determine target mRNA reduction and t-PA mRNA expression.
Results were only used when target reduction was at least 80%.
Two negative controls were used for siRNA, in one the
DharmaFECT 4 transfection reagent was added alone to cells
(mock), in another a control siRNA was used (All Star Negative
control, Qiagen). No difference in expression of t-PA or target
gene was observed with either control.
Microarray analysis
Gene expression in VPA-treated and untreated HUVECs from
4 donors was analyzed using the Human Gene 1.0 ST microarray
(Affymetrix). Target preparation and hybridization to the DNA
microarray were performed according to standard Affymetrix
protocols at the Uppsala Array Platform (Uppsala, Sweden). Raw
data from the arrays are MIAME compliant and have been
deposited in the Gene Expression Omnibus (GEO) database (raw
data available at: http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=dnglzumweoisshk&acc=GSE23909). Raw data was
analyzed using the RMA (robust multi-array average) method
implemented in the Affymetrix software Expression Console.
Probe sets with a log2 ratio above +1 or below 21 and a
significantly changed expression (p,0.05, false discovery rate
(FDR) adjusted p-value) were classified as regulated. Hemostasis
genes were identified using the Amigo database (http://amigo.
geneontology.org). The regulation of these genes, as well as
all genes up and down regulated by VPA can be found in table S1.
Statistics
Data are presented as mean and standard error of the mean. All
comparisons are specified in the figure legends and were
performed between samples from the same experiment and
time-point to check for statistical significance. Unless otherwise
stated in figure legends, the statistical evaluation was performed
using paired Student’s t-test. A p-value of less than 0.05 was
considered significant. For analysis of time series data, two-way
analysis of variance (ANOVA) for repeated measures was used.
Results
Valproic acid induces t-PA mRNA expression and protein
secretion
Incubation of HUVEC cultures with VPA for 24 h caused a
significant concentration-dependent increase in t-PA mRNA
expression, evident already at concentrations as low as 0.3 mM
(p,0.05) and reaching a maximum at 3–4 mM (Fig. 1A). At the
maximal concentrations, t-PA mRNA levels were increased 9-fold
after 24 h. The levels of t-PA protein released into the medium
during VPA stimulation were comparably (8-fold) induced
(Fig. 1B). There was a somewhat less pronounced effect of VPA
on t-PA secretion during the second 24 h-period of culture (48 h)
but maximal protein induction was still maintained on an
approximately 5-fold increase (data not shown).
To verify that this effect of VPA was present also in a more
representative endothelial cell type, we incubated HCAEC with
VPA and measured t-PA mRNA expression (Fig. 1C) and protein
secretion (Fig. 1D). A comparable response pattern as in HUVEC
could be observed in this cell type after 24 h, with an 8- and 5-fold
increase in mRNA and protein, respectively. Similar mRNA and
protein levels could also be detected for the time period 24–48 h
(data not shown).
In order to investigate the temporal response pattern we
exposed HUVECs to a clinically relevant concentration (1 mM) as
well as to the maximum in vitro tolerated concentration (4 mM) of
VPA for up to 72 h and measured t-PA mRNA levels (Fig. 1E).
For the 1 mM dose, a ,4-fold steady-state induction was reached
after 12 h and this level of induction remained throughout the
VPA Increases t-PA Expression in Endothelial Cells
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(4 mM) was somewhat different with an initial transient peak
induction of about 12-fold at 24 h, which gradually leveled-off to
about 4-fold at 72 h.
We also compared the effect of VPA (2-propylpentanoic acid)
on t-PA expression to that of valpromide (2-propylpentanamide), a
structural amide analogue of VPA reported to lack HDAC
inhibitory activity [14,19]. Whereas 4 mM of VPA increased t-PA
levels 9-fold, the same concentration of valpromide had no effect
on expression of t-PA mRNA in HUVECs (Fig. 2A). Moreover, we
confirmed that the t-PA induction by VPA is not due to altered
pH, as pH was identical (7.28) in EGM-2 medium with/
without 3 mM VPA after over-night incubation at 37uC, 5%
CO2.
Valproic acid increases acetylation of histones H3 and H4
To confirm that VPA acts as an HDAC inhibitor in endothelial
cells we performed western blot assays with antibodies to
acetylated as well as to total histone H3 and H4. These
experiments showed an increase of global acetylated histone H3
and H4 after VPA treatment, whereas no induction of total histone
proteins could be detected (Fig. 2B).
Figure 1. Effects of valproic acid (VPA) on mRNA and protein expression in HUVEC and HCAEC. HUVEC (A and B) and HCAEC (C and D)
were exposed to different concentrations (0.1–4 mM) of VPA for 24 h. mRNA (A and C) was quantified with real-time PCR and secreted t-PA protein
(B and D) in conditioned media by ELISA. Values are expressed as fold change over control cells. The shaded areas show the plasma concentration
range of VPA achieved after clinical VPA treatment. E. HUVECs were treated with 1 mM or 4 mM of VPA and t-PA mRNA quantified after 6, 12, 24, 48
and 72 h. The results show mean values 6 SEM of three independent experiments (n=3) performed in duplicate. For Fig. 1E statistical significance
was tested using 2-way ANOVA for repeated measures: p(dose),0.01, p(time),0.01 and p(dose6time),0.001.
doi:10.1371/journal.pone.0031573.g001
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at the t-PA gene regulatory region, ChIP-analyses were performed
using antibodies to pan-acetylated histone H3 and H4, and
primers flanking the major t-PA transcription initiation site. This
showed a significant 2-fold increase of both acetylated H3 and H4
associated with the region surrounding the major t-PA transcrip-
tion start site after VPA treatment (Fig. 3A and B). We went on to
examine which specific lysine residues in histone H3 and H4 that
were acetylated after VPA treatment. Antibodies for specific lysine
modifications were also used in ChIP assays and demonstrated a
significant increase of acetylation of lysines 9, 18, 23 and 27 on
histone H3 as well as lysines 8 and 16 on histone H4 (Fig. 3C and
D). Acetylation of H3K14 was undetectable in this system,
whereas H4K5 and K12 acetylation was not significantly changed
after VPA treatment.
siRNA knock-down of class I, IIa and IV HDACs does not
block t-PA induction by VPA
As VPA has been reported to selectively inhibit class I and IIa
HDACs, each HDAC enzyme in these two groups was indepen-
dently depleted with siRNA to identify its potential role in basal as
well as VPA-induced t-PA gene expression (Fig. 4 and 5).HDAC11,
the only class IV HDAC, was also included in these studies.
Treatment of cells with HDAC1, HDAC2, HDAC4, HDAC5,
HDAC7, HDAC9 and HDAC11 siRNA had no effect on basal t-
PA mRNA expression. However, a modest induction of t-PA
mRNA was observed in HDAC3 (67%, p,0.01) and HDAC8
(225%, p,0.05) depleted cells, compared to untreated controls.
Single depletion of any of the 9 tested HDACs was not sufficient
to block the VPA-response, as all cells challenged with VPA
showed significant inductions of t-PA (p,0.05 or below compared
to untreated controls, as well as respective siRNA treated control).
However, the magnitude of the t-PA induction was partially
reduced with HDAC3, HDAC5 and HDAC7 siRNA treatments.
HDAC3 depleted cells showed a modest reduction from 12-fold
induction of t-PA in untreated control cells to 9-fold (p,0.05). In
HDAC5 and HDAC7 siRNA treated cells the VPA-response was
more profoundly weakened; for HDAC5 from 9-fold to 5-fold and
for HDAC7 from 6.5-fold to 3.5 fold (both p,0.01).
Valproic acid causes a selective stimulation of gene
expression in endothelial cells
In order to determine the effect of high dose VPA on global
gene expression, microarray analysis was performed on HUVEC
cells after exposure to maximal concentration (4 mM) of VPA for
24 h. On a global scale, a relatively small number of genes, 2.6%,
were affected by this treatment. Out of these, not all were up-
regulated, but 37% were actually suppressed by the treatment.
When looking more specifically at genes involved in hemostatic
pathways, the expression levels of the majority of transcripts were
not significantly affected by VPA (Fig. 6). Of the 138 genes
annotated as being involved in hemostasis (131 unique genes and 7
with 2 probe sets), only 4 genes were up-regulated and 2 genes
suppressed. Indeed, the hemostatic gene that was most strongly
regulated by VPA was t-PA.
The relative lack of effect of VPA on plasminogen activator
inhibitor-1 (PAI-1), urokinase plasminogen activator (u-PA), and
von Willebrand (vWF) factor in the array was confirmed by real-
time PCR. Maximal doses of VPA only caused a minor,
approximately 30%, increase of both PAI-1 and u-PA, and a
30% decrease of vWF transcript (data not shown).
Discussion
In search of a clinically eligible pharmacological tool to enhance
or restore an impaired endogenous fibrinolysis, previous studies
have mainly focused on the transcriptional regulation of t-PA via
classic transcription factor/cis-element interactions. However, two
studies by Kooistra el al [9,10] and a recent study by the group of
Kruithof [11] have suggested that the t-PA gene could be sensitive
to changes in histone acetylation status. In light of these findings
we investigated whether the putative HDAC-inhibitory activity of
valproic acid (VPA) [13,14], a clinically used and generally well-
tolerated anti-epileptic drug, could enhance t-PA synthesis in
human endothelial cells. We found that VPA markedly increased
t-PA mRNA expression and protein secretion in two different
endothelial cell types with a dose-dependent response. Important-
ly, this effect was evident at low, clinically relevant concentrations
with a significant increase already at 0.3 mM, and reaching a
maximum of approximately 10-fold induction.
Next, we investigated if this profound effect of VPA on t-PA
production in endothelial cells was indeed related to the ability of
the drug to modify histone acetylation status. Western blot analysis
of VPA-treated HUVECs showed increased total histone acety-
lation, confirming that VPA functions as an HDAC inhibitor in
this cell type. Moreover, the VPA analogue valpromide (VPM), a
substance lacking HDACi activity [14,19], failed to induce t-PA in
endothelial cells. To determine whether VPA affects acetylation
status of histones associated specifically with the t-PA promoter we
performed ChIP analyses with antibodies directed against
acetylated histone H3 and H4, and primers spanning the major
transcription start site. Using pan-acetyl H3 and H4 antibodies,
detecting acetylation at a number of different lysines, we observed
a significant increase of acetylated histones associated with the
Figure 2. Dependence of HDAC-inhibitory activity for t-PA
induction and effect of VPA on global histone acetylation. A. t-
PA mRNA expression in HUVECs stimulated with 4 mM VPA or 4 mM
VPM (a structural amide analogue of VPA which is reported to lack
HDAC inhibitory activity) for 24 h. The results are presented as mean
values 6 SEM of five independent experiments performed in duplicate.
**p,0.01. B. HUVECs were exposed to 3 mM VPA for 24 h after which
cells were harvested in Laemmli sample buffer for analysis of global
acetylation of histone H3 and H4 by Western blotting. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0031573.g002
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hypothesis that it is the HDACi activity of VPA that specifically
causes the increase in transcription. This is also in accordance with
the recently published study by Kruithof and coworkers who noted
increased acetylation of histones associated with the t-PA
regulatory region 1 kb upstream of the major transcription start
site after treatment of HUVEC with the HDACi TSA or MS-275
[11].
Recent accumulating evidence points to the existence of a
histone code that is recognized and interpreted by effector proteins
with chromatin modifying activities [20]. There are also data
implying that certain specific modifications directly influence
higher-order chromatin structure and compaction. To confirm the
results from the pan-acetyl antibody ChIPs and to get a more
detailed view of the acetylation code surrounding the t-PA
transcription start site, we looked more specifically at individual
lysine acetylation in this region using lysine-specific antibodies. We
found that the majority of the H3 lysines covered by the pan-acetyl
antibody (K9, 14, 18, 23, and 27) were differentially acetylated
after VPA stimulation. For H4, we could detect increased
acetylation at two out of four potential acetylation sites, namely
K8 and K16. Acetylation of H4K16 specifically has been reported
to have a strong influence on higher-order chromatin structure
[21]. Interestingly, this was one of the histone acetylation marks at
the t-PA promoter that was most noticeably induced after VPA
stimulation, perhaps indicating that compaction of chromatin in
Figure 4. siRNA mediated knock-down of class I HDACs. t-PA
mRNA expression in HUVECs treated with class I HDAC-targeting siRNAs
for 72 h and then stimulated with 3 mM VPA for 24 h. Mock indicate
cells treated with DharmaFECT 4 transfection reagent alone and ASN
indicate cells transfected with All Star Negative control siRNA (Qiagen).
Unless indicated in the figure, statistical comparisons are made relative
to untreated control cells. *p,0.05, **p,0.01. The results are presented
as mean values 6 SEM of four independent experiments performed in
duplicate.
doi:10.1371/journal.pone.0031573.g004
Figure 3. Chromatin Immunoprecipitation (ChIP) for acetylated histones in the t-PA promoter. HUVECs were exposed to 3 mM of VPA
for 24 h after which cells were fixed and chromatin harvested. ChIP-analyses for acetylated histone H3 and H4 were performed with real-time PCR
primers flanking the major t-PA transcription start site. Data are presented as percent input corrected for background binding and mean values 6
SEM of four to five independent experiments are shown. A. ChIP for pan-acetylated histone H3. n=4.B. ChIP for pan-acetylated H4. n=5.C. ChIP for
specific histone H3 acetylation. Antibodies for monoacetylated acH3K9, acH3K18, acH3K23 and acH3K27 were used. n=4.D. ChIP for specific histone
H4 acetylation. Antibodies for monoacetylated acH4K5, acH4K8, acH4K12 and acH4K16 were used. n=5.*p,0.05, **p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0031573.g003
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these results support the hypothesis that it is indeed the VPA
HDAC inhibitory property per se that stimulates t-PA production.
Given that the HDACi function of VPA seems important for the
regulation of t-PA we wanted to determine the role of the
individual HDACs in regulation of t-PA both constitutively and in
the VPA response. VPA was initially suggested to be a HDAC
class I selective inhibitor [13]. More recent data suggest that VPA
inhibits HDACs of both the class I and class II subfamilies (IC50
approximately 1 mM), only discriminating against the class IIb
HDACs (HDAC6 and HDAC10) which are not inhibited [22].
However, Dunoyer-Geindre et al has recently implied the
importance of the class I HDACs in the regulation of t-PA [11].
To extend this study and to test the potential dependence of each
single HDAC, we performed siRNA knockdown of the class I
(HDAC1, 2, 3, and 8), IIa (HDAC4, 5, 7, and 9) and class IV
(HDAC11) HDACs and investigated the effect of VPA in these
HDAC deficient cells. Although we observed a weakened VPA-
response with HDAC3, HDAC5 and HDAC7 depletion, these
experiments showed that no single HDAC of class I, IIa and IV is
crucial for the induction of t-PA by VPA. It is therefore likely that
these factors are redundant and in order to block the effect of
VPA, simultaneous knock-down of several HDACs might be
required.
Considering that VPA increased global histone acetylation in
endothelial cells and acetylation is regarded as a permissive
Figure 5. siRNA mediated knock-down of class IIa and class IV HDACs. t-PA mRNA expression in HUVECs treated with A. HDAC4, B. HDAC5,
C. HDAC7, D. HDAC9 and E. HDAC11-targeting siRNA for 72 h and then stimulated with 3 mM VPA for 24 h. Mock indicate cells treated with
DharmaFECT 4 transfection reagent alone and ASN indicate cells transfected with All Star Negative control siRNA (Qiagen). Unless indicated in the
figure, statistical comparisons are made relative to untreated control cells. *p,0.05, **p,0.01. The results are presented as mean values 6 SEM of
four independent experiments performed in duplicate (HDAC9, n=2).
doi:10.1371/journal.pone.0031573.g005
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a generalized increase in gene expression, and that, accordingly,
the induction of t-PA expression may be a non-specific effect. To
clarify this issue we performed transcription profiling on HUVECs
treated with VPA for 24 h, assaying the effect of VPA on
approximately 28,000 human genes. Somewhat unexpectedly, the
effect of the treatment on global gene expression was quite limited.
Only a total of 2.6% of all genes were significantly modified. Out
of these, 37% were actually suppressed indicating that HDAC
inhibition is not always a stimulatory mechanism but may also
suppress gene expression, perhaps via up-regulation of regulatory
proteins that are repressors of transcription or mediators of RNA
instability [23]. In line with our findings, previous array studies
with other HDAC inhibitors have indicated that only a small
number of genes, about 2–5%, are in fact affected by HDAC
inhibitors [24,25] in various cell types.
In further support of our hypothesis that the t-PA gene is
particularly sensitive to histone acetylation, out of the 138
hemostasis-related genes identified in the AMIGO database, we
found that the most powerfully regulated gene was in fact t-PA.
The related fibrinolytic gene u-PA and the main inhibitor of t-PA,
PAI-1, were only marginally affected by the treatment, which was
also confirmed by real-time PCR. Of note, it has been suggested
that genes that are dependent on the Sp1 transcription factor for
transcription (TATA-less genes) are often negatively regulated by
HDACs and greatly induced by HDAC-inhibitors [26,27,28,29].
Interestingly, t-PA belongs to this group of genes, as its promoter
contains three Sp1 binding GC-boxes reported to be crucial for
constitutive t-PA expression [30,31]. Sp1 has been shown to
recruit cofactors with both HAT and HDAC activities [32,33,34]
and it is possible that HDAC inhibition affects the balance of these
activities in this region hence changing gene expression. As
HDACs also are known to de-acetylate many non-histone proteins
including Sp1, it is also possible that HDAC inhibition results in
acetylation of the Sp1 protein itself potentially changing its DNA
binding affinity or protein-protein interactions [34].
Even though the data presented here show an effect of VPA on
t-PA production in vitro, it remains to be determined whether VPA
treatment could be used clinically for stimulation of endogenous
fibrinolytic capacity in vivo. VPA has been extensively used in
epilepsy treatment and its profile of adverse effects is well known,
the majority of side effects are mild, reversible, and occurring
mainly at high plasma concentrations [35]. More severe adverse
effects may occur in children (hepatotoxicity) and pregnant women
(teratogenicity), but these groups are rarely considered for
cardiovascular prevention. Interestingly, concentrations compara-
ble to those in the lower therapeutic plasma concentration range
(0.3–0.5 mM) caused a significant 2–3 fold increase of t-PA
synthesis. Unfortunately, endothelial t-PA release is difficult to
assess in vivo since it requires arterial cannulation with local organ
measurement due to the rapid degradation of t-PA by the liver
with highly variable clearances rates [36]. If, however, a similar
enhancement of t-PA production could be obtained in patients
treated with valproic acid it could theoretically reduce the risk of
acute atherothrombotic disorders. Indeed, Olesen et al recently
reported a 40% reduced risk of myocardial infarction in a Danish
nation-wide study of epileptic patients treated with VPA [37].
Even though VPA has been reported to affect several aspects of the
hemostatic system [35], it is conceivable that a substantial part of
this reduced risk could be attributable to enhanced t-PA
production.
In summary, this is to our knowledge the first time that an
already approved and registered pharmacological agent has been
shown to potentiate t-PA expression in clinically relevant
concentrations in vitro and hence VPA may open up an
opportunity for pharmacological modulation of the fibrinolytic
system in vivo.
Supporting Information
Table S1 Regulation of global endothelial gene expres-
sion by VPA. The table lists data obtained from microarray
experiments on HUVECs treated with 4 mM VPA for 24 h. The
table is divided into genes up-regulated by VPA, genes down-regulated by
VPA and a complete list on regulation of all hemostasis genes by VPA.
Hemostasis genes were identified using the Amigo database
(http://amigo.geneontology.org). Presented data are mean of four
individual experiments and are listed as fold change compared to
untreated control cells.
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